Dr. Urba is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4805 Ne Glisan St
6n40
Portland, OR 97213Phone+1 503-215-5696Fax+1 503-215-5695
Summary
- Dr. Walter Urba is an oncologist in Portland, OR and is affiliated with Providence Portland Medical Center. He received his Ph.D. in Immunology from UCLA and his medical degree from University of Miami Miller School of Medicine. He completed his medical oncology fellowship at the NCI. He specializes in medical oncology with expertise in immuno-oncology. He is director of the Robert W. Franz Cancer Center, Earle A. Chiles Research Institute and physician director of research for Providence in Oregon.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
- Atlantic Health System/Morristown Medical CenterResidency, Internal Medicine, 1981 - 1983
- University of Miami Leonard M. Miller School of MedicineClass of 1981
Certifications & Licensure
- NJ State Medical License 1982 - Present
- OR State Medical License 1993 - 2025
- MD State Medical License 1984 - 1993
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Portland Monthly Magazine Castle Connolly, 2011
- Join now to see all
Clinical Trials
- Vaccine Therapy in Treating Women With Metastatic Breast Cancer Start of enrollment: 1996 Aug 01
- Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2004 Jul 01
- The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2006 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System.Alexa K Dowdell, Ryan C Meng, Ann Vita, Bela Bapat, Douglas Hanes
JCO Oncology Practice. 2024-11-01 - Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu
Journal of Clinical Oncology. 2024-09-20 - 3 citationsCobimetinib Plus Vemurafenib in Patients With Solid Tumors WithMutations: Results From the Targeted Agent and Profiling Utilization Registry Study.Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Rodolfo Gutierrez
JCO Precision Oncology. 2023-09-01
Journal Articles
- The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin-6 Signaling in COVID-19-Related Systemic Inflammatory ResponseSteven J O'Day, Walter J Urba, Jeffrey S Weber, Journal For Immunotherapy of Cancer
Press Mentions
- Providence Cancer Institute in Oregon Taps New LeaderNovember 15th, 2024
- Germinal Center Reactions in Tertiary Lymphoid Structures Associate with Neoantigen Burden, Humoral Immunity and Long-Term Survivorship in Pancreatic CancerMarch 17th, 2021
- Germinal Center Reactions in Tertiary Lymphoid Structures Associate with Neoantigen Burden, Humoral Immunity and Long-Term Survivorship in Pancreatic CancerDecember 8th, 2020
- Join now to see all
Grant Support
- Clinical Trial Of Dribble Vaccine In NsclcNational Cancer Institute2008–2009
- Peptide Booster Vaccination In A2+ Melanoma PatientsNational Cancer Institute2004–2005
- GP100 Peptide Immunization After Lymphocyte DepletionNational Cancer Institute2003–2004
- Immune Response To The Mutated Gp?00 Peptide (209o-2m)National Cancer Institute2000
- Immune Response To The Mutated GP 100 Peptide (209o 2m)National Cancer Institute1999
- Vaccination With B7-Transfected Breast Cancer CellsNational Cancer Institute1996–1997
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: